1) H2N-Ala-Ala-Ala-Xn-Resin (189 mg, 0.1 mmol) was prepared using Fmoc chemistry on Rink amide MBHA resin.
2) H2N-Ala-Ala-Ala-Xn-Resin (0.1 mmol) was dissolved in anhydrous DMF (10 mL) at ambient temperature, and swelled for 20 min. N-Acetyl-L-cysteine ( 98mg, 0.3 mmol, 3.0 equiv) and DMAP (26 mg, 0.1 mmol, 1.0 equiv) was added, and the reaction was degassed, UV irradiated for 1 h with stirring. After photo reaction, the resin was washed with DCM for three times and then with methanol to shrink the resin. The resin was dried under a steam of argon gas for 1 hour.
3) The dried peptide-containing resin was placed in a polypropylene container with a screw cap, then cleavage cocktail (2.0 mL, TFA/TIS/EDT/H2O 94/1/2.5/2.5) was added and the container was sealed tightly with screw cap. The container was gently agitated on an orbital shaker in the fume hood for 2 h. The TFA cocktail was removed with by evaporation under a steam of argon gas in the fume hood, and the residue was precipitated with cold diethyl ether 3×3 ml.
4) The precipitate was dried and dissolved in 100 mL dry DMF, and then HATU (115 mg, 0.3 mmol) and DIEA (82 uL, 0.5 mmol) were added at 0 °C. The mixture was stirred overnight and then concentrated in vacuo. The residue was dissolved in H2O and purified on HPLC.
General procedure B. Thiolether linker was constructed through on-resin cyclization.
Ac-Cys(Trt)-Ala-Ala-Ala-Xn-Resin (189 mg, 0.1 mmol) was prepared using Fmoc chemistry on Rink amide MBHA resin. 1) Ac-Cys(Trt)-Ala-Ala-Ala-Xn-Resin (0.1mmol) was treated with 2 mL scavenger (TFA/TIS/DCM 0.03/0.06/1.0) for 1 h to remove Trt protection.
2) Ac-Cys-Ala-Ala-Ala-Xn-Resin was dried and re-dissolved in 5 mL DMF, and then DMPA (26 mg, 0.1 mmol) was added and stirred under UV irradiation of 0.5 -1 h.
The resin was washed with DMF and DCM for three times, and then shrink with methanol. The resin was dried with a steam of argon gas for 1 h.
3) The dried peptide-containing resin was placed in a polypropylene container with a screw cap, then cleavage cocktail (2.0 mL, TFA/TIS/EDT/H2O 94/1/2.5/2.5) was added and the container was sealed tightly with screw cap. The container was gently agitated on an orbital shaker in the fume hood for 2 h. The TFA cocktail was removed by evaporation under a steam of argon gas in the fume hood, and the residue was precipitated with cold diethyl ether 3×3 ml. The residue was dissolved in H2O/acetonitrile 1:1 and purified on HPLC or used directly in the oxidation procedure.
General procedure C. This procedure was the same with General procedure A except for that Rink amide resin and N-Acetyl-L-cysteine were change to CTC resin and L-Cysteinamide monohydrochloride.
Characterization of peptide 1-26
Peptide 1 was synthesized following general procedure A. 15mg (32% isolated). Peptide 2 (10 mg) was dispersed in 5% H2O2 5 mL and the mixture was stirred for 3 h at ambient temperature, the result clear solution was purified on HPLC directly. Peptide 3 (10 mg) was dispersed in 5% H2O2 5 mL and the mixture was stirred for 3 h at ambient temperature, the result clear solution was purified on HPLC directly. 11AB Peptide 8 (10 mg) was dispersed in 5% H2O2 5 mL and the mixture was stirred for 3 h at ambient temperature, the result clear solution was purified on HPLC directly. The thiolether peptide Ac-c(1,5)-[X5AIAC]-NH2 (0.3 mmol) was synthesized following general procedure C. After remove DMF, the precipitate was dissolved in 5% H2O2 (5 mL) and the mixture was stirred at room temperature for 3 h. Then the solution was purified on RP HPLC. Table 1 . SI. Figure 9 . CD spectrum of Peptide 19B dissolved in 10mM PBS and MeOH/H2O (1:1).
10A 3 mg (29% isolated). General analytical method

16A 4 mg (39% isolated). General analytical method
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